Anti-mullerian hormone receptor type 2 transcript variants encoding different isoforms have been identified. [provided by RefSeq, Sep 2009]. Anti-mullerian hormone receptor type 2 Anti-Mullerian hormone receptor type 2 is a protein that in humans is encoded by the AMHR2 gene. This gene encodes the receptor for the anti-Mullerian hormone (AMH) which, in addition to testosterone, results in male sex differentiation. AMH and testosterone are produced in the testes by different cells and have different effects. Testosterone promotes the development of male genitalia while the binding of AMH to the encoded receptor prevents the development of the mullerian ducts into uterus and Fallopian tubes. Mutations in
Transgender hormone therapy Transgender hormone therapy Transgender hormone therapy, also sometimes called cross-sex hormone therapy, is a form of hormone replacement therapy (HRT) in which sex hormones and other hormonal medications are administered to transgender or gender nonconforming individuals for the purpose of more closely aligning their secondary sexual characteristics with their gender identity. This form of HRT is given as one of two types, based on whether the goal of treatment is feminization or masculinization: Some intersex people may also undergo HRT, either starting in childhood to confirm the sex they were assigned at birth, or later in order to align their